APEX BIOTECHNOLOGY CORPORATION
Previous company name
Name change date
Apex Biotechnology Corp., established in December 1997, is a Taiwanese-based company engaged in the research, development and manufacture of biotechnological products. The company’s corporate office is located in Hsinchu, Taiwan.
Apex Biotechnology offers blood glucose monitoring systems, uric acid monitoring systems, blood lactate monitoring systems and testing strips used on the management of chronic diseases; the screening for acute conditions. The company manufactures up to 40,000 monitors and 22,000,000 test strips monthly. It distributes its products within the domestic market and to overseas markets, including the rest of Asia, the Americas, Europe and Africa.
Apex Biotechnology is a leading manufacturer of blood glucose testing and other biosensor-related monitoring systems specially designed for the healthcare industry. It is also Taiwan’s largest manufacture of blood glucosemonitors.
Apex Biotechnology’s quality assurance process and standards have been set out in accordance with ISO9001:2000, ISO13485 and EN46001.
Apex Biotechnology aims to produce user-friendly and affordable blood glucose monitoring systems for diabetic patients.
The Company is principally engaged in the research, development and manufacture of biotechnological products. Its products include blood glucose monitoring system and blood uric acid monitoring system.
Description and history
The Company was established in December 1997 and is principally engaged in the research, development and manufacture of biotechnological products. The Company listed on TSEC in 2001.
FDA 510 (k) approval of the GlucoSure Voice Blood Glucose Monitoring System. Approval number K073137.
Awarded by Forbes Asia as “200 Best under a Billion” three years in a row.
A1c Xpress POC HbA1c and Hemoglobin Analyzer awarded as “Innovative Product of the Year” at Taipei Mediphar Trade Show.
Awarded by Forbes Asia ‘200 Best under a billion’
Awarded by Frost & Sullivan as ‘Healthcare Award for Upcoming Medical Device Company of the year’
Awarded by Forbes Asia as ‘200 Best under a billion’.
Passed 2nd FDA on-site inspection.
Li-Hsin new facility start to operate.
Move-in New Facility.
Co-Development of Bioluminesence Microsystems with ITRI.
Purchasing of a new facility (23,867 M2).
MultiSure Glucose & Uric Acid System Product Launch.
Move-in new factory site (6,600 M2)
1.MultiSure Glucose & Uric Acid System – Industrial Technology Advancement award from the MOEA Dec.
2.HbA1c Project – Subsidy granted from IDB.
Small business innovation research award from the MOEA.
Listed on the Taiwan Stock Exchange (stock code 1733)
Passed 1st FDA on-site inspection.
Listed on the Taiwan Over-The-Counter Securities Exchange.
GlucoSure Blood Glucose Monitoring System launch.
Sensorex Blood Monitoring System wom ‘Product of the year’ on Mediphar, Taipei.
Engaged in the research, development and manufacture of biotechnological products
APEXBIO INVESTMENT LIMITED
DELOITTE & TOUCHE
US SIC Code
Hsinchu Science Park
7, Li-Hsin Road V.
City province or state postal code
Phone: +886 3 564 1952
Fax: +886 3 567 8302
Country address: TAIWAN
Website url: www.apexbio.com